Study of Befotertinib for non-small cell lung cancer with uncommon EGFR mutations
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a drug called Befotertinib for people with non-small cell lung cancer that has uncommon EGFR mutations (like G719X, L861Q, S768I, or exon 20 insertions). It is for those who haven't taken an EGFR-targeted pill before and have had a previous chemotherapy stopped working or caused side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and your daily activity level is reasonably good (ECOG 0-2).
- You have advanced or spread non-small cell lung cancer confirmed by a biopsy.
- Your tumor has a specific uncommon change in the EGFR gene: either G719X, L861Q, S768I, or an insertion in exon 20.
- You have not been treated with a pill that targets EGFR (like osimertinib or erlotinib) before.
- Your cancer worsened or you could not tolerate at least one round of standard platinum chemotherapy.
- You have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted medicines (befotertinib and bevacizumab) before surgery for people with EGFR-mutant non-small cell lung cancer that cannot be removed right away. The goal is to see if this treatment can shrink the tumor and improve surgery outcomes.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This trial tests a pill called befortinib for people with early-stage lung cancer who have had surgery. It aims to lower the chance of the cancer coming back. You might qualify if your tumor had certain high-risk features and you still have cancer DNA in your blood after surgery.
This trial tests a new drug, befotertinib, combined with chemotherapy as a first treatment for advanced lung cancer with an EGFR mutation. It aims to see if this approach can improve outcomes and uses a special blood test to guide treatment adjustments.
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
This trial tests a targeted therapy (Befotertinib) combined with radiation for people with a specific EGFR mutation whose lung cancer has spread to a few spots. It aims to see if ctDNA monitoring can guide treatment.
Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.